[Editor's Note] At a recent academic conference, Professor Ben Tran from the Peter MacCallum Cancer Centre and the University of Melbourne presented the preliminary results of the CLIMATE study (ANZUP 1906). This prospective cohort study aimed to evaluate the clinical utility of microRNA-371a-3p (miR-371) as a marker for minimal residual disease (MRD) in predicting relapse in patients with clinical stage 1 (CS1) testicular germ cell tumors (TGCTs).01 Clinical Challenges: Monitoring and Overtreatment in CS1 Testicular Cancer
Active surveillance is currently the standard of care for the majority of patients with CS1 TGCT. However, Professor Tran pointed out that existing risk assessment tools lack sufficient precision, leading to unnecessary treatment and potential toxicity for patients who might otherwise be cured by orchiectomy alone. There is an urgent clinical need for more sensitive and specific biomarkers to identify patients with true MRD, thereby optimizing the selection of adjuvant therapies.
02 Biomarker Selection: Plasma Testing Outperforms Serum
miR-371 is a highly expressed biomarker in TGCT patients with a very short half-life. The CLIMATE study prospectively compared the detection performance of serum versus plasma samples.
- Methodology: 200 CS1 TGCT patients were enrolled, with samples collected within 6 weeks (median 29 days) post-orchiectomy.
- Performance Comparison: Results showed that plasma testing significantly outperformed serum in predicting relapse, with an area under the curve (AUC) of 0.77 for plasma versus 0.69 for serum (P=0.04).
- Precision Data: In this interim analysis, the plasma miR-371 test demonstrated a positive predictive value (PPV) of 62% and a negative predictive value (NPV) of 91%.
03 MRD Predictive Value: Strong Association with Relapse Risk
The study data indicate that baseline plasma miR-371 status post-orchiectomy is strongly associated with relapse-free survival (RFS).
- Statistical Analysis: Patients with a positive baseline plasma miR-371 faced an extremely high risk of relapse, with a hazard ratio (HR) of 10.3 (P<0.001).
- 24-Month RFS Benefit: Patients with baseline miR-371 negativity achieved a 24-month RFS rate of 89%, compared to only 32% in the positive group. These findings confirm miR-371 as a reliable indicator for identifying MRD and distinguishing high-risk populations.
04 Comparative Performance: Challenging Traditional Clinical Risk Factors
The CLIMATE study compared miR-371 against existing clinicopathological risk factors:
- Pure Seminoma: miR-371 achieved an AUC of 0.86, significantly outperforming traditional risk grading criteria and tumor size metrics.
- Non-Seminoma: The miR-371 AUC was 0.72, likewise outperforming traditional predictors such as lymphovascular invasion (LVI) and the percentage of embryonal carcinoma (EC) components.
Data suggest that miR-371 consistently exhibits superior diagnostic utility across all histological types, offering the potential for refined risk stratification to guide clinical decision-making.
05 Limitations and Relapse Specificity
Professor Tran objectively addressed the study’s limitations, including the relatively small sample size and the short median follow-up period (18.9 months).
- False Negatives: 14 patients who initially tested negative at baseline experienced relapse (these were primarily non-seminoma cases with late relapse).
- Detection at Relapse: Only 2 patients tested negative at the time of relapse; one represented a clinical teratoma recurrence (which is biologically known to be typically miR-371 negative), and the other showed only elevated classical markers.
Conclusion and Outlook
The interim results of the CLIMATE study confirm that post-orchiectomy miR-371 is a key MRD marker for CS1 testicular cancer, outperforming current clinical evaluation indicators. This finding has the potential to reshape CS1 TGCT clinical practice by enabling precise risk stratification, reducing overtreatment, and ensuring timely adjuvant intervention for high-risk patients. Future efforts will focus on finalizing sample analysis, dynamic monitoring, and international validation.
